Genome-wide association and sequencing studies on colorectal cancer

Seminars in Cancer Biology

Volumn 23, Issue 6 PB, 2013, Pages 502-511

  Wong, Sunny H ^a   Sung, Joseph J Y ^a   Chan, Francis K L ^a   To, Ka F ^b   Ng, Simon S M ^b   Wang, Xiao J ^a   Yu, Jun ^a   Wu, William K K ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

Colorectal cancer; GWAS; Mutation; Next generation sequencing

Indexed keywords

FLUOROURACIL; IRINOTECAN; TRANSFORMING GROWTH FACTOR BETA;

ASIAN; CARCINOGENESIS; CAUCASIAN; CHROMOSOMAL INSTABILITY; COLORECTAL CANCER; COLORECTAL CARCINOMA; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC PROCEDURES; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HERITABILITY; HUMAN; INTESTINE FLORA; METAGENOMICS; MICROSATELLITE INSTABILITY; MOLECULAR CLONING; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; NONHUMAN; REVIEW; SANGER SEQUENCING; SINGLE CELL SEQUENCING; STATISTICAL ANALYSIS;

COLORECTAL CANCER; GWAS; MUTATION; NEXT-GENERATION SEQUENCING;

ANIMALS; COLORECTAL NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MUTATION; SIGNAL TRANSDUCTION;

EID: 84887618161     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2013.09.005     Document Type: Review

References (159)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. Cancer Journal for Clinicians 2011, 61:69-90.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. Cancer Journal for Clinicians 2013, 63:11-30.
3. Chan A.T., Giovannucci E.L. Primary prevention of colorectal cancer. Gastroenterology 2010, 138(2029-43):e10.
4. Kostic A.D., Chun E., Robertson L., Glickman J.N., Gallini C.A., Michaud M., et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host & Microbe 2013, 14:207-215.
5. Rubinstein M.R., Wang X., Liu W., Hao Y., Cai G., Han Y.W. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin. Cell Host & Microbe 2013, 14:195-206.
6. McCoy A.N., Araujo-Perez F., Azcarate-Peril A., Yeh J.J., Sandler R.S., Keku T.O. Fusobacterium is associated with colorectal adenomas. PLoS One 2013, 8:e53653.
7. Chen W., Liu F., Ling Z., Tong X., Xiang C. Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer. PLoS One 2012, 7:e39743.
8. Kostic A.D., Gevers D., Pedamallu C.S., Michaud M., Duke F., Earl A.M., et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Research 2012, 22:292-298.
9. Castellarin M., Warren R.L., Freeman J.D., Dreolini L., Krzywinski M., Strauss J., et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Research 2012, 22:299-306.
10. Wu W.K., Wang X.J., Cheng A.S., Luo M.X., Ng S.S., To K.F., et al. Dysregulation and crosstalk of cellular signaling pathways in colon carcinogenesis. Critical Reviews in Oncology/Hematology 2013, 86:251-277.
11. Kilpivaara O., Aaltonen L.A. Diagnostic cancer genome sequencing and the contribution of germline variants. Science 2013, 339:1559-1562.
12. Peters U., Jiao S., Schumacher F.R., Hutter C.M., Aragaki A.K., Baron J.A., et al. Identification of genetic susceptibility loci for colorectal tumors in a genome-wide meta-analysis. Gastroenterology 2013, 144(799-807):e24.
13. Theodoratou E., Montazeri Z., Hawken S., Allum G.C., Gong J., Tait V., et al. Systematic meta-analyses and field synopsis of genetic association studies in colorectal cancer. Journal of the National Cancer Institute 2012, 104:1433-1457.
14. Cancer Genome Atlas N Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-337.
15. Bass A.J., Lawrence M.S., Brace L.E., Ramos A.H., Drier Y., Cibulskis K., et al. Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nature Genetics 2011, 43:964-968.
16. Dienstmann R., Rodon J., Barretina J., Tabernero J. Genomic medicine frontier in human solid tumors: prospects and challenges. Journal of Clinical Oncology 2013, 31:1874-1884.
17. Mwenifumbo J.C., Marra M.A. Cancer genome-sequencing study design. Nature Reviews Genetics 2013, 14:321-332.
18. Meyerson M., Gabriel S., Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nature Reviews Genetics 2010, 11:685-696.
19. Amos C.I. Successful design and conduct of genome-wide association studies. Human Molecular Genetics 2007, 16(Spec No. 2):R220-R225.
20. Weitz J., Koch M., Debus J., Hohler T., Galle P.R., Buchler M.W. Colorectal cancer. Lancet 2005, 365:153-165.
21. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767.
22. Rex D.K., Ahnen D.J., Baron J.A., Batts K.P., Burke C.A., Burt R.W., et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. American Journal of Gastroenterology 2012, 107:1315-1329.
23. Chan T.L., Zhao W., Leung S.Y., Yuen S.T., Cancer Genome P. BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas. Cancer Research 2003, 63:4878-4881.
24. Park S.J., Rashid A., Lee J.H., Kim S.G., Hamilton S.R., Wu T.T. Frequent CpG island methylation in serrated adenomas of the colorectum. American Journal of Pathology 2003, 162:815-822.
25. Pritchard C.C., Grady W.M. Colorectal cancer molecular biology moves into clinical practice. Gut 2011, 60:116-129.
26. Burrell R.A., McClelland S.E., Endesfelder D., Groth P., Weller M.C., Shaikh N., et al. Replication stress links structural and numerical cancer chromosomal instability. Nature 2013, 494:492-496.
27. Duhamel S., Hebert J., Gaboury L., Bouchard A., Simon R., Sauter G., et al. Sef downregulation by Ras causes MEK1/2 to become aberrantly nuclear localized leading to polyploidy and neoplastic transformation. Cancer Research 2012, 72:626-635.
28. Nam H.J., Chae S., Jang S.H., Cho H., Lee J.H. The PI3K-Akt mediates oncogenic Met-induced centrosome amplification and chromosome instability. Carcinogenesis 2010, 31:1531-1540.
29. Hadjihannas M.V., Bruckner M., Jerchow B., Birchmeier W., Dietmaier W., Behrens J. Aberrant Wnt/beta-catenin signaling can induce chromosomal instability in colon cancer. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:10747-10752.
30. Koinuma K., Shitoh K., Miyakura Y., Furukawa T., Yamashita Y., Ota J., et al. Mutations of BRAF are associated with extensive hMLH1 promoter methylation in sporadic colorectal carcinomas. International Journal of Cancer 2004, 108:237-242.
31. Mirabelli-Primdahl L., Gryfe R., Kim H., Millar A., Luceri C., Dale D., et al. Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. Cancer Research 1999, 59:3346-3351.
32. Ahuja N., Mohan A.L., Li Q., Stolker J.M., Herman J.G., Hamilton S.R., et al. Association between CpG island methylation and microsatellite instability in colorectal cancer. Cancer Research 1997, 57:3370-3374.
33. Sinicrope F.A., Sargent D.J. Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2012, 18:1506-1512.
34. Fallik D., Borrini F., Boige V., Viguier J., Jacob S., Miquel C., et al. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Research 2003, 63:5738-5744.
35. Lander E.S. The new genomics: global views of biology. Science 1996, 274:536-539.
36. Risch N., Merikangas K. The future of genetic studies of complex human diseases. Science 1996, 273:1516-1517.
37. International HapMap C., Frazer K.A., Ballinger D.G., Cox D.R., Hinds D.A., Stuve L.L., et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007, 449:851-861.
38. Jia W.H., Zhang B., Matsuo K., Shin A., Xiang Y.B., Jee S.H., et al. Genome-wide association analyses in East Asians identify new susceptibility loci for colorectal cancer. Nature Genetics 2013, 45:191-196.
39. Cui R., Okada Y., Jang S.G., Ku J.L., Park J.G., Kamatani Y., et al. Common variant in 6q26-q27 is associated with distal colon cancer in an Asian population. Gut 2011, 60:799-805.
40. Tenesa A., Farrington S.M., Prendergast J.G., Porteous M.E., Walker M., Haq N., et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nature Genetics 2008, 40:631-637.
41. Tomlinson I., Webb E., Carvajal-Carmona L., Broderick P., Kemp Z., Spain S., et al. A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nature Genetics 2007, 39:984-988.
42. Zanke B.W., Greenwood C.M., Rangrej J., Kustra R., Tenesa A., Farrington S.M., et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nature Genetics 2007, 39:989-994.
43. Thean L.F., Li H.H., Teo Y.Y., Koh W.P., Yuan J.M., Teoh M.L., et al. Association of Caucasian-identified variants with colorectal cancer risk in Singapore Chinese. PLoS One 2012, 7:e42407.
44. Lubbe S.J., Whiffin N., Chandler I., Broderick P., Houlston R.S. Relationship between 16 susceptibility loci and colorectal cancer phenotype in 3146 patients. Carcinogenesis 2012, 33:108-112.
45. Li M., Zhou Y., Chen P., Yang H., Yuan X., Tajima K., et al. Genetic variants on chromosome 8q24 and colorectal neoplasia risk: a case-control study in China and a meta-analysis of the published literature. PLoS One 2011, 6:e18251.
46. He J., Wilkens L.R., Stram D.O., Kolonel L.N., Henderson B.E., Wu A.H., et al. Generalizability and epidemiologic characterization of eleven colorectal cancer GWAS hits in multiple populations. Cancer Epidemiology, Biomarkers & Prevention 2011, 20:70-81.
47. von Holst S., Picelli S., Edler D., Lenander C., Dalen J., Hjern F., et al. Association studies on 11 published colorectal cancer risk loci. British Journal of Cancer 2010, 103:575-580.
48. Xiong F., Wu C., Bi X., Yu D., Huang L., Xu J., et al. Risk of genome-wide association study-identified genetic variants for colorectal cancer in a Chinese population. Cancer Epidemiology, Biomarkers & Prevention 2010, 19:1855-1861.
49. Middeldorp A., Jagmohan-Changur S., van Eijk R., Tops C., Devilee P., Vasen H.F., et al. Enrichment of low penetrance susceptibility loci in a Dutch familial colorectal cancer cohort. Cancer Epidemiology, Biomarkers & Prevention 2009, 18:3062-3067.
50. Curtin K., Lin W.Y., George R., Katory M., Shorto J., Cannon-Albright L.A., et al. Meta association of colorectal cancer confirms risk alleles at 8q24 and 18q21. Cancer Epidemiology, Biomarkers & Prevention 2009, 18:616-621.
51. Wokolorczyk D., Gliniewicz B., Sikorski A., Zlowocka E., Masojc B., Debniak T., et al. A range of cancers is associated with the rs6983267 marker on chromosome 8. Cancer Research 2008, 68:9982-9986.
52. Berndt S.I., Potter J.D., Hazra A., Yeager M., Thomas G., Makar K.W., et al. Pooled analysis of genetic variation at chromosome 8q24 and colorectal neoplasia risk. Human Molecular Genetics 2008, 17:2665-2672.
53. Tuupanen S., Niittymaki I., Nousiainen K., Vanharanta S., Mecklin J.P., Nuorva K., et al. Allelic imbalance at rs6983267 suggests selection of the risk allele in somatic colorectal tumor evolution. Cancer Research 2008, 68:14-17.
54. Poynter J.N., Figueiredo J.C., Conti D.V., Kennedy K., Gallinger S., Siegmund K.D., et al. Variants on 9p24 and 8q24 are associated with risk of colorectal cancer: results from the Colon Cancer Family Registry. Cancer Research 2007, 67:11128-11132.
55. Haiman C.A., Le Marchand L., Yamamato J., Stram D.O., Sheng X., Kolonel L.N., et al. A common genetic risk factor for colorectal and prostate cancer. Nature Genetics 2007, 39:954-956.
56. Tomlinson I.P., Webb E., Carvajal-Carmona L., Broderick P., Howarth K., Pittman A.M., et al. A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nature Genetics 2008, 40:623-630.
57. Broderick P., Carvajal-Carmona L., Pittman A.M., Webb E., Howarth K., Rowan A., et al. A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk. Nature Genetics 2007, 39:1315-1317.
58. Hong S.N., Park C.H., Kim J.I., Kim D.H., Kim H.C., Chang D.K., et al. Colorectal cancer-susceptibility single nucleotide polymorphisms in Korean population. Journal of Gastroenterology and Hepatology 2013, in press. 10.1111/jgh.12331.
59. Houlston R.S., Webb E., Broderick P., Pittman A.M., Di Bernardo M.C., Lubbe S., et al. Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nature Genetics 2008, 40:1426-1435.
60. Li J., Sun C., Yuan Y., Liu L., Xiong G., Wu J. Bone morphogenetic protein-4 polymorphism and colorectal cancer risk: a meta analysis. Molecular Biology Reports 2012, 39:5239-5251.
61. Lubbe S.J., Pittman A.M., Olver B., Lloyd A., Vijayakrishnan J., Naranjo S., et al. The 14q22.2 colorectal cancer variant rs4444235 shows cis-acting regulation of BMP4. Oncogene 2012, 31:3777-3784.
62. Peters U., Hutter C.M., Hsu L., Schumacher F.R., Conti D.V., Carlson C.S., et al. Meta-analysis of new genome-wide association studies of colorectal cancer risk. Human Genetics 2012, 131:217-234.
63. Fernandez-Rozadilla C., Palles C., Carvajal-Carmona L., Peterlongo P., Nici C., Veneroni S., et al. BMP2/BMP4 colorectal cancer susceptibility loci in northern and southern European populations. Carcinogenesis 2013, 34:314-318.
64. Zheng X., Wang L., Zhu Y., Guan Q., Li H., Xiong Z., et al. The SNP rs961253 in 20p12.3 is associated with colorectal cancer risk: a case-control study and a meta-analysis of the published literature. PLoS One 2012, 7:e34625.
65. Jaeger E., Webb E., Howarth K., Carvajal-Carmona L., Rowan A., Broderick P., et al. Common genetic variants at the CRAC1 (HMPS) locus on chromosome 15q13.3 influence colorectal cancer risk. Nature Genetics 2008, 40:26-28.
66. Giraldez M.D., Lopez-Doriga A., Bujanda L., Abuli A., Bessa X., Fernandez-Rozadilla C., et al. Susceptibility genetic variants associated with early-onset colorectal cancer. Carcinogenesis 2012, 33:613-619.
67. Qin Q., Liu L., Zhong R., Zou L., Yin J., Zhu B., et al. The genetic variant on chromosome 10p14 is associated with risk of colorectal cancer: results from a case-control study and a meta-analysis. PLoS One 2013, 8:e64310.
68. Zou L., Zhong R., Lou J., Lu X., Wang Q., Yang Y., et al. Replication study in Chinese population and meta-analysis supports association of the 11q23 locus with colorectal cancer. PLoS One 2012, 7:e45461.
69. Houlston R.S., Cheadle J., Dobbins S.E., Tenesa A., Jones A.M., Howarth K., et al. Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. Nature Genetics 2010, 42:973-977.
70. Zhang T., Li X., Du Q., Gong S., Wu M., Mao Z., et al. DUSP10 gene polymorphism and risk of colorectal cancer in the Han Chinese population. European Journal of Cancer Prevention 2013, in press. 10.1097/CEJ.0b013e3283647408.
71. Ma X., Zhang B., Zheng W. Genetic variants associated with colorectal cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. Gut 2013, in press. 10.1136/gutjnl-2012-304121.
72. Kinnersley B., Migliorini G., Broderick P., Whiffin N., Dobbins S.E., Casey G., et al. The TERT variant rs2736100 is associated with colorectal cancer risk. British Journal of Cancer 2012, 107:1001-1008.
73. Hofer P., Baierl A., Bernhart K., Leeb G., Mach K., Micksche M., et al. Association of genetic variants of human telomerase with colorectal polyps and colorectal cancer risk. Molecular Carcinogenesis 2012, 51(Suppl 1):E176-E182.
74. Dunlop M.G., Dobbins S.E., Farrington S.M., Jones A.M., Palles C., Whiffin N., et al. Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nature Genetics 2012, 44:770-776.
75. Lichtenstein P., Holm N.V., Verkasalo P.K., Iliadou A., Kaprio J., Koskenvuo M., et al. Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. New England Journal of Medicine 2000, 343:78-85.
76. Jasperson K.W., Tuohy T.M., Neklason D.W., Burt R.W. Hereditary and familial colon cancer. Gastroenterology 2010, 138:2044-2058.
77. Aaltonen L., Johns L., Jarvinen H., Mecklin J.P., Houlston R. Explaining the familial colorectal cancer risk associated with mismatch repair (MMR)-deficient and MMR-stable tumors. Clinical Cancer Research 2007, 13:356-361.
78. Gudmundsson J., Sulem P., Manolescu A., Amundadottir L.T., Gudbjartsson D., Helgason A., et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nature Genetics 2007, 39:631-637.
79. Haiman C.A., Patterson N., Freedman M.L., Myers S.R., Pike M.C., Waliszewska A., et al. Multiple regions within 8q24 independently affect risk for prostate cancer. Nature Genetics 2007, 39:638-644.
80. Amundadottir L.T., Sulem P., Gudmundsson J., Helgason A., Baker A., Agnarsson B.A., et al. A common variant associated with prostate cancer in European and African populations. Nature Genetics 2006, 38:652-658.
81. Gabriel S.B., Schaffner S.F., Nguyen H., Moore J.M., Roy J., Blumenstiel B., et al. The structure of haplotype blocks in the human genome. Science 2002, 296:2225-2229.
82. Wasserman N.F., Aneas I., Nobrega M.A. An 8q24 gene desert variant associated with prostate cancer risk confers differential in vivo activity to a MYC enhancer. Genome Research 2010, 20:1191-1197.
83. Wright J.B., Brown S.J., Cole M.D. Upregulation of c-MYC in cis through a large chromatin loop linked to a cancer risk-associated single-nucleotide polymorphism in colorectal cancer cells. Molecular and Cellular Biology 2010, 30:1411-1420.
84. Pomerantz M.M., Ahmadiyeh N., Jia L., Herman P., Verzi M.P., Doddapaneni H., et al. The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nature Genetics 2009, 41:882-884.
85. Tuupanen S., Turunen M., Lehtonen R., Hallikas O., Vanharanta S., Kivioja T., et al. The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nature Genetics 2009, 41:885-890.
86. Sweet K., Willis J., Zhou X.P., Gallione C., Sawada T., Alhopuro P., et al. Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis. Journal of the Ameican Medical Association 2005, 294:2465-2473.
87. Howe J.R., Roth S., Ringold J.C., Summers R.W., Jarvinen H.J., Sistonen P., et al. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science 1998, 280:1086-1088.
88. Howe J.R., Ringold J.C., Summers R.W., Mitros F.A., Nishimura D.Y., Stone E.M. A gene for familial juvenile polyposis maps to chromosome 18q21.1. American Journal of Human Genetics 1998, 62:1129-1136.
89. Liao R.Y., Mao C., Qiu L.X., Ding H., Chen Q., Pan H.F. TGFBR1*6A/9A polymorphism and cancer risk: a meta-analysis of 13,662 cases and 14,147 controls. Molecular Biology Reports 2010, 37:3227-3232.
90. Valle L., Serena-Acedo T., Liyanarachchi S., Hampel H., Comeras I., Li Z., et al. Germline allele-specific expression of TGFBR1 confers an increased risk of colorectal cancer. Science 2008, 321:1361-1365.
91. Ku J.L., Park S.H., Yoon K.A., Shin Y.K., Kim K.H., Choi J.S., et al. Genetic alterations of the TGF-beta signaling pathway in colorectal cancer cell lines: a novel mutation in SMAD3 associated with the inactivation of TGF-beta-induced transcriptional activation. Cancer Letters 2007, 247:283-292.
92. Zhang H.T., Zhao J., Zheng S.Y., Chen X.F. Is TGFBR1*6A really associated with increased risk of cancer?. Journal of Clinical Oncology 2005, 23:7743-7744.
93. Ando T., Sugai T., Habano W., Jiao Y.F., Suzuki K. Analysis of SMAD4/DPC4 gene alterations in multiploid colorectal carcinomas. Journal of Gastroenterology 2005, 40:708-715.
94. Salovaara R., Roth S., Loukola A., Launonen V., Sistonen P., Avizienyte E., et al. Frequent loss of SMAD4/DPC4 protein in colorectal cancers. Gut 2002, 51:56-59.
95. Ilyas M., Efstathiou J.A., Straub J., Kim H.C., Bodmer W.F. Transforming growth factor beta stimulation of colorectal cancer cell lines: type II receptor bypass and changes in adhesion molecule expression. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:3087-3091.
96. Thiagalingam S., Lengauer C., Leach F.S., Schutte M., Hahn S.A., Overhauser J., et al. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nature Genetics 1996, 13:343-346.
97. Parsons R., Myeroff L.L., Liu B., Willson J.K., Markowitz S.D., Kinzler K.W., et al. Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Research 1995, 55:5548-5550.
98. Levy L., Hill C.S. Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. Cytokine & Growth Factor Reviews 2006, 17:41-58.
99. Peck J.W., Oberst M., Bouker K.B., Bowden E., Burbelo P.D. The RhoA-binding protein, rhophilin-2, regulates actin cytoskeleton organization. Journal of Biological Chemistry 2002, 277:43924-43932.
100. Chang Y.W., Marlin J.W., Chance T.W., Jakobi R. RhoA mediates cyclooxygenase-2 signaling to disrupt the formation of adherens junctions and increase cell motility. Cancer Research 2006, 66:11700-11708.
101. Devilee P., van Vliet M., Kuipers-Dijkshoorn N., Pearson P.L., Cornelisse C.J. Somatic genetic changes on chromosome 18 in breast carcinomas: is the DCC gene involved?. Oncogene 1991, 6:311-315.
102. Bodmer W.F., Bailey C.J., Bodmer J., Bussey H.J., Ellis A., Gorman P., et al. Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature 1987, 328:614-616.
103. Forrester K., Almoguera C., Han K., Grizzle W.E., Perucho M. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature 1987, 327:298-303.
104. Wood L.D., Parsons D.W., Jones S., Lin J., Sjoblom T., Leary R.J., et al. The genomic landscapes of human breast and colorectal cancers. Science 2007, 318:1108-1113.
105. Sjoblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314:268-274.
106. Wang Z., Shen D., Parsons D.W., Bardelli A., Sager J., Szabo S., et al. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science 2004, 304:1164-1166.
107. Bardelli A., Parsons D.W., Silliman N., Ptak J., Szabo S., Saha S., et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 2003, 300:949.
108. van de Wetering M., Sancho E., Verweij C., de Lau W., Oving I., Hurlstone A., et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002, 111:241-250.
109. Rosin-Arbesfeld R., Townsley F., Bienz M. The APC tumour suppressor has a nuclear export function. Nature 2000, 406:1009-1012.
110. Tetsu O., McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999, 398:422-426.
111. Mann B., Gelos M., Siedow A., Hanski M.L., Gratchev A., Ilyas M., et al. Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:1603-1608.
112. He T.C., Sparks A.B., Rago C., Hermeking H., Zawel L., da Costa L.T., et al. Identification of c-MYC as a target of the APC pathway. Science 1998, 281:1509-1512.
113. Murata M., Iwao K., Miyoshi Y., Nagasawa Y., Yabu M., Himeno S., et al. Activation of the beta-catenin gene by interstitial deletions involving exon 3 as an early event in colorectal tumorigenesis. Cancer Letters 2000, 159:73-78.
114. Yun J., Rago C., Cheong I., Pagliarini R., Angenendt P., Rajagopalan H., et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 2009, 325:1555-1559.
115. Ries S., Biederer C., Woods D., Shifman O., Shirasawa S., Sasazuki T., et al. Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell 2000, 103:321-330.
116. Okada F., Rak J.W., Croix B.S., Lieubeau B., Kaya M., Roncari L., et al. Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:3609-3614.
117. Bieging K.T., Attardi L.D. Deconstructing p53 transcriptional networks in tumor suppression. Trends in Cell Biology 2012, 22:97-106.
118. Elyada E., Pribluda A., Goldstein R.E., Morgenstern Y., Brachya G., Cojocaru G., et al. CKIalpha ablation highlights a critical role for p53 in invasiveness control. Nature 2011, 470:409-413.
119. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304:554.
120. Baba Y., Nosho K., Shima K., Hayashi M., Meyerhardt J.A., Chan A.T., et al. Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers. Cancer 2011, 117:1399-1408.
121. Shao J., Evers B.M., Sheng H. Roles of phosphatidylinositol 3'-kinase and mammalian target of rapamycin/p70 ribosomal protein S6 kinase in K-Ras-mediated transformation of intestinal epithelial cells. Cancer Research 2004, 64:229-235.
122. Itoh N., Semba S., Ito M., Takeda H., Kawata S., Yamakawa M. Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer 2002, 94:3127-3134.
123. Wang Q., Wang X., Hernandez A., Kim S., Evers B.M. Inhibition of the phosphatidylinositol 3-kinase pathway contributes to HT29 and Caco-2 intestinal cell differentiation. Gastroenterology 2001, 120:1381-1392.
124. Welcker M., Clurman B.E. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nature Reviews Cancer 2008, 8:83-93.
125. Zhuang G., Song W., Amato K., Hwang Y., Lee K., Boothby M., et al. Effects of cancer-associated EPHA3 mutations on lung cancer. Journal of the National Cancer Institute 2012, 104:1182-1197.
126. Day B.W., Stringer B.W., Al-Ejeh F., Ting M.J., Wilson J., Ensbey K.S., et al. EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme. Cancer Cell 2013, 23:238-248.
127. Seshagiri S., Stawiski E.W., Durinck S., Modrusan Z., Storm E.E., Conboy C.B., et al. Recurrent R-spondin fusions in colon cancer. Nature 2012, 488:660-664.
128. Hao H.X., Xie Y., Zhang Y., Charlat O., Oster E., Avello M., et al. ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner. Nature 2012, 485:195-200.
129. Timmermann B., Kerick M., Roehr C., Fischer A., Isau M., Boerno S.T., et al. Somatic mutation profiles of MSI and MSS colorectal cancer identified by whole exome next generation sequencing and bioinformatics analysis. PLoS One 2010, 5:e15661.
130. Yin H., Liang Y., Yan Z., Liu B., Su Q. Mutation spectrum in human colorectal cancers and potential functional relevance. BMC Medical Genetics 2013, 14:32.
131. Han S.W., Kim H.P., Shin J.Y., Jeong E.G., Lee W.C., Lee K.H., et al. Targeted sequencing of cancer-related genes in colorectal cancer using next-generation sequencing. PLoS One 2013, 8:e64271.
132. Schork N.J., Murray S.S., Frazer K.A., Topol E.J. Common vs. rare allele hypotheses for complex diseases. Current Opinion in Genetics & Development 2009, 19:212-219.
133. Dickson S.P., Wang K., Krantz I., Hakonarson H., Goldstein D.B. Rare variants create synthetic genome-wide associations. PLoS Biology 2010, 8:e1000294.
134. Rivas M.A., Beaudoin M., Gardet A., Stevens C., Sharma Y., Zhang C.K., et al. Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nature Genetics 2011, 43:1066-1073.
135. Luo L., Boerwinkle E., Xiong M. Association studies for next-generation sequencing. Genome Research 2011, 21:1099-1108.
136. Lee S., Wu M.C., Lin X. Optimal tests for rare variant effects in sequencing association studies. Biostatistics 2012, 13:762-775.
137. Ley R.E., Peterson D.A., Gordon J.I. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 2006, 124:837-848.
138. Damman C.J., Miller S.I., Surawicz C.M., Zisman T.L. The microbiome and inflammatory bowel disease: is there a therapeutic role for fecal microbiota transplantation?. American Journal of Gastroenterology 2012, 107:1452-1459.
139. Turnbaugh P.J., Ley R.E., Mahowald M.A., Magrini V., Mardis E.R., Gordon J.I. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006, 444:1027-1031.
140. Qin J., Li R., Raes J., Arumugam M., Burgdorf K.S., Manichanh C., et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010, 464:59-65.
141. Qin J., Li Y., Cai Z., Li S., Zhu J., Zhang F., et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012, 490:55-60.
142. Sokol H., Seksik P., Furet J.P., Firmesse O., Nion-Larmurier I., Beaugerie L., et al. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflammatory Bowel Diseases 2009, 15:1183-1189.
143. Favier C., Neut C., Mizon C., Cortot A., Colombel J.F., Mizon J. Fecal beta-d-galactosidase production and bifidobacteria are decreased in Crohn's disease. Digestive Diseases and Sciences 1997, 42:817-822.
144. Strauss J., Kaplan G.G., Beck P.L., Rioux K., Panaccione R., Devinney R., et al. Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host. Inflammatory Bowel Diseases 2011, 17:1971-1978.
145. Zong C., Lu S., Chapman A.R., Xie X.S. Genome-wide detection of single-nucleotide and copy-number variations of a single human cell. Science 2012, 338:1622-1626.
146. Hou Y., Song L., Zhu P., Zhang B., Tao Y., Xu X., et al. Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm. Cell 2012, 148:873-885.
147. Xu X., Hou Y., Yin X., Bao L., Tang A., Song L., et al. Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell 2012, 148:886-895.
148. Li Y., Xu X., Song L., Hou Y., Li Z., Tsang S., et al. Single-cell sequencing analysis characterizes common and cell-lineage-specific mutations in a muscle-invasive bladder cancer. GigaScience 2012, 1:12.
149. Parsons B.L. Many different tumor types have polyclonal tumor origin: evidence and implications. Mutation Research 2008, 659:232-247.
150. Kreso A., O'Brien C.A., van Galen P., Gan O.I., Notta F., Brown A.M., et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 2013, 339:543-548.
151. Ding L., Ley T.J., Larson D.E., Miller C.A., Koboldt D.C., Welch J.S., et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012, 481:506-510.
152. Bardou M., Barkun A.N., Martel M. Obesity and colorectal cancer. Gut 2013, 62:933-947.
153. Sung J.J., Lau J.Y., Goh K.L., Leung W.K., Asia Pacific Working Group on Colorectal C. Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncology 2005, 6:871-876.
154. Cotillard A., Kennedy S.P., Kong L.C., Prifti E., Pons N., Le Chatelier E., et al. Dietary intervention impact on gut microbial gene richness. Nature 2013, 500:585-588.
155. Katsanis S.H., Katsanis N. Molecular genetic testing and the future of clinical genomics. Nature Reviews Genetics 2013, 14:415-426.
156. Richman S.D., Seymour M.T., Chambers P., Elliott F., Daly C.L., Meade A.M., et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. Journal of Clinical Oncology 2009, 27:5931-5937.
157. Merok M.A., Ahlquist T., Royrvik E.C., Tufteland K.F., Hektoen M., Sjo O.H., et al. Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: results from a large, consecutive Norwegian series. Annals of Oncology 2013, 24:1274-1282.
158. Weiser M.R., Gonen M., Chou J.F., Kattan M.W., Schrag D. Predicting survival after curative colectomy for cancer: individualizing colon cancer staging. Journal of Clinical Oncology 2011, 29:4796-4802.
159. Amado R.G., Wolf M., Peeters M., Van Cutsem E., Siena S., Freeman D.J., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. Journal of Clinical Oncology 2008, 26:1626-1634.